Calidi Biotherapeutics (CLDI) Cash from Operations (2022 - 2025)
Calidi Biotherapeutics (CLDI) posted quarterly Cash from Operations of 5051000.0 for Q4 2025, up 6.86% year-over-year from 4726759.79 in Q4 2024, and down 19.18% quarter-over-quarter from 4238000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Cash from Operations (2022 - 2025) Analysis & Trends
Calidi Biotherapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 5051000.0 for Q4 2025.
- In Q4 2025, Cash from Operations rose 6.86% year-over-year to 5051000.0; the TTM figure through Dec 2025 stood at 21300000.0 (down 8.15% YoY), while the FY2025 annual figure was 21300000.0, down 8.15% from the prior year.
- Cash from Operations for Q4 2025 stood at 5051000.0, down from 4238000.0 in the prior quarter.
- The five-year high for Cash from Operations was 268679.0 in Q2 2022, with the low at 13517000.0 in Q3 2023.
- The 4-year median for Cash from Operations is 4998500.0 (2024), against an average of 5074437.5.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations plunged 1825.35% in 2023, then surged 63.41% in 2024.
- Calidi Biotherapeutics' Cash from Operations stood at 3876000.0 in 2022, then sank by 33.8% to 5186000.0 in 2023, then declined by 4.57% to 5423000.0 in 2024, then advanced by 6.86% to 5051000.0 in 2025.
- Business Quant data shows CLDI's Cash from Operations at 5051000.0 in Q4 2025, 4238000.0 in Q3 2025, and 4880000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -5.05 Mn |
| Dec 31, 2025 | -5.05 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Jun 30, 2025 | -4.88 Mn |
| Jun 30, 2025 | -4.88 Mn |
| Mar 31, 2025 | -7.13 Mn |
| Mar 31, 2025 | -7.13 Mn |
| Dec 31, 2024 | -5.42 Mn |
| Dec 31, 2024 | -5.42 Mn |
| Sep 30, 2024 | -4.95 Mn |
| Sep 30, 2024 | -4.95 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Jun 30, 2024 | -5.49 Mn |
| Mar 31, 2024 | -3.83 Mn |
| Mar 31, 2024 | -3.83 Mn |
| Dec 31, 2023 | -5.19 Mn |
| Dec 31, 2023 | -5.19 Mn |
| Sep 30, 2023 | -13.52 Mn |
| Sep 30, 2023 | -13.52 Mn |